Casdin Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Casdin Capital’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.06M	Buy	186,014 +100,000	+116%	+$1.91M	0.23%	32
2025 Q4	$1.35M	Hold	86,014	–	–	0.08%	34
2025 Q3	$637K	Hold	86,014	–	–	0.05%	29
2025 Q2	$388K	Hold	86,014	–	–	0.04%	32
2025 Q1	$399K	Hold	86,014	–	–	0.03%	41
2024 Q4	$597K	Hold	86,014	–	–	0.04%	37
2024 Q3	$456K	Sell	86,014 -175,000	-67%	-$883K	0.03%	33
2024 Q2	$976K	Sell	261,014 -249,868	-49%	-$1.27M	0.07%	35
2024 Q1	$3.6M	Hold	510,882	–	–	0.27%	30
2023 Q4	$2.89M	Hold	510,882	–	–	0.28%	32
2023 Q3	$2.45M	Hold	510,882	–	–	0.27%	34
2023 Q2	$3.5M	Hold	510,882	–	–	0.31%	32
2023 Q1	$3.98M	Hold	510,882	–	–	0.33%	34
2022 Q4	$3.89M	Hold	510,882	–	–	0.3%	40
2022 Q3	$4.17M	Hold	510,882	–	–	0.27%	29
2022 Q2	$4.94M	Sell	510,882 -450,000	-47%	-$4.52M	0.42%	29
2022 Q1	$13.5M	Hold	960,882	–	–	0.6%	31
2021 Q4	$19.6M	Sell	960,882 -1	-0%	-$21	0.55%	36
2021 Q3	$21.4M	Hold	960,883	–	–	0.53%	38
2021 Q2	$21.8M	Buy	+960,883	New	+$19.6M	0.55%	35

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Casdin Capital's GLUE Position: Q1 2026 in Review

Casdin Capital increased its Monte Rosa Therapeutics (GLUE) stake by 116% in Q1 2026, buying an estimated $1.91M and bringing the position to 186,014 shares worth $3.06M. The position accounts for 0.23% of the portfolio, ranked #32.

Casdin Capital first reported a position in GLUE in Q2 2021 and has held it in 20 quarters since. The position peaked at $21.8M in Q2 2021. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Casdin Capital held 186,014 shares of Monte Rosa Therapeutics worth $3.06M as of Q1 2026.
Casdin Capital bought 100,000 Monte Rosa Therapeutics shares in Q1 2026, an estimated $1.91M.
Monte Rosa Therapeutics made up 0.23% of Casdin Capital's portfolio in Q1 2026, its #32 holding.
Casdin Capital first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 20 quarters since.
Casdin Capital's Monte Rosa Therapeutics position peaked at $21.8M in Q2 2021.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.